EyePoint Pharmaceuticals Files Q1 2025 10-Q
Ticker: EYPT · Form: 10-Q · Filed: May 8, 2025 · CIK: 1314102
| Field | Detail |
|---|---|
| Company | Eyepoint Pharmaceuticals, Inc. (EYPT) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, corporate-actions
TL;DR
EYPT Q1 2025 10-Q filed. Financials and operational updates out.
AI Summary
EyePoint Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as pSivida Corp., is incorporated in Delaware and headquartered in Watertown, MA. Key financial reporting dates include March 31, 2025, and December 31, 2024. The filing references various accounting standards and company-specific plans, including equity incentive plans and product rights agreements.
Why It Matters
This filing provides investors with an update on EyePoint Pharmaceuticals' financial performance and operational status for the first quarter of 2025, crucial for understanding the company's trajectory.
Risk Assessment
Risk Level: medium — The filing is a standard quarterly report, but the company's specific industry and financial health can introduce inherent risks.
Key Numbers
- 20250331 — Period End Date (The end of the reporting quarter for this 10-Q filing.)
- 20250508 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- EyePoint Pharmaceuticals, Inc. (company) — Filer of the 10-Q
- pSivida Corp. (company) — Former name of EyePoint Pharmaceuticals
- 20250331 (date) — Period of report for the 10-Q
- 20250508 (date) — Filing date of the 10-Q
- 480 Pleasant Street, Suite B300, Watertown, MA 02472 (location) — Business and mailing address
FAQ
What is the primary business of EyePoint Pharmaceuticals, Inc.?
The filing lists the Standard Industrial Classification as 'LABORATORY ANALYTICAL INSTRUMENTS [3826]', suggesting a focus in this area, though the company's specific products are not detailed in this excerpt.
When did EyePoint Pharmaceuticals change its name from pSivida Corp.?
The date of the name change from pSivida Corp. to EyePoint Pharmaceuticals, Inc. was June 19, 2008.
What is the fiscal year end for EyePoint Pharmaceuticals?
The fiscal year end for EyePoint Pharmaceuticals is December 31.
What specific accounting standards or plans are referenced in the filing excerpt?
The filing excerpt references accounting standards such as 'OtherLiabilitiesCurrent', 'AccountsPayableCurrent', and company-specific plans like 'EquityIncentivePlansAndInducementAwardGrantsMember', 'OcumensionTherapeuticsMember', and 'ProductRightsAgreementMember'.
What is the SEC file number for EyePoint Pharmaceuticals?
The SEC file number for EyePoint Pharmaceuticals is 000-51122.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding EyePoint Pharmaceuticals, Inc. (EYPT).